Mepolizumab, a humanized monoclonal antibody that targets interleukin-5 (IL-5), significantly reduced COPD exacerbations in ...

The FDA granted approval to mepolizumab for treating adults with inadequately controlled COPD and an eosinophilic phenotype, according to a GSK press release.This is the second biologic approved as an ...

New findings from the MATINEE and COPD-HELP studies suggest mepolizumab could reduce exacerbations and improve quality of life in patients with eosinophilic chronic obstructive pulmonary disease (COPD ...

Mepolizumab targets IL-5, addressing eosinophilic inflammation in 20%-40% of COPD patients, marking its fifth US indication. The phase 3 MATINEE trial showed a 21% reduction in annualized moderate ...

If you continue to have this issue please contact [email protected]. Patients receiving mepolizumab vs. placebo had a smaller number of moderate/severe exacerbations at weeks 52 and 104.

GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab)as an add-on maintenance treatment for adult patients with inadequately ...

Compared with placebo, the time to first moderate or severe exacerbation was longer with mepolizumab. HealthDay News — For patients with chronic obstructive pulmonary disease (COPD) with a ...

The FDA approved mepolizumab (Nucala) for adults with inadequately controlled chronic obstructive pulmonary disease (COPD), drugmaker GSK announced on Thursday. Labeling for the interleukin-5 (IL-5) ...

The FDA has approved Nucala (mepolizumab) for the add-on maintenance treatment of patients with inadequately controlled eosinophilic COPD.

Patients were randomly assigned to receive mepolizumab 100 mg or placebo subcutaneously every four weeks for 52 to 104 weeks (403 and 401 individuals, respectively). The researchers found that the ...

The US Food and Drug Administration (FDA) has approved mepolizumab as a maintenance treatment for chronic obstructive ...

The researchers found that the annualized rate of moderate or severe exacerbations was significantly lower with mepolizumab than placebo (0.80 versus 1.01 events per year; rate ratio, 0.79).